Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma

Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia

(2013) Shukui Qin et al.   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

(2013) Ann-Lii Cheng et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma

(2012) Thomas Yau et al.   INVESTIGATIONAL NEW DRUGS

Deprivation of arginine by recombinant human arginase in prostate cancer cells

(2012) Eddy C Hsueh et al.   Journal of Hematology & Oncology

Pegylated arginase I: a potential therapeutic approach in T-ALL

(2010) C. P. Hernandez et al.   BLOOD

A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients

(2010) T-S Yang et al.   BRITISH JOURNAL OF CANCER

Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis

(2010) Tin-Lun Lam et al.   Pigment Cell & Melanoma Research

Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC)

(2009) Sam-Mui Tsui et al.   Cancer Cell International

Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest

(2009) T.L. Lam et al.   CANCER LETTERS

A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy

(2008) Thomas Yau et al.   CANCER

Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase

(2008) Tawnya L. Bowles et al.   INTERNATIONAL JOURNAL OF CANCER

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE